nach oben

Medical Microbiology and Immunology

Erschienen in:

01.02.2015 | Review

Natural history of chronic hepatitis B virus infection

verfasst von: Katrin Busch, Robert Thimme

Erschienen in: Medical Microbiology and Immunology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Hepatitis B virus infection represents a major global health problem. Currently, there are more than 240 million chronically infected people worldwide. The development of chronic hepatitis B virus-mediated liver disease may lead to liver fibrosis, cirrhosis and eventually hepatocellular carcinoma. Recently, the discovery of the viral entry receptor sodium taurocholate cotransporting polypeptide has facilitated new approaches for a better understanding of viral physiopathology. Hopefully, these novel insights may give rise to the development of more effective antiviral therapy concepts during the next years. In this review, we will discuss the natural history of hepatitis B virus infection including the viral biology, the clinical course of infection and the role of the immune response.

Suh A, Brosius J, Schmitz J, Kriegs JO (2013) The genome of a Mesozoic paleovirus reveals the evolution of hepatitis B viruses. Nat Commun 4:1791PubMedCrossRef

Gilbert C, Feschotte C (2010) Genomic fossils calibrate the long-term evolution of hepadnaviruses. PLoS Biol 8(9):e1000495PubMedCentralPubMedCrossRef

Locarnini S, Littlejohn M, Aziz MN, Yuen L (2013) Possible origins and evolution of the hepatitis B virus (HBV). Semin Cancer Biol 23(6 Pt B):561–575PubMedCrossRef

Paraskevis D, Magiorkinis G, Magiorkinis E, Ho SY, Belshaw R et al (2013) Dating the origin and dispersal of hepatitis B virus infection in humans and primates. Hepatology 57(3):908–916PubMedCrossRef

Kahila Bar-Gal G, Kim MJ, Klein A, Shin DH, Oh CS et al (2012) Tracing hepatitis B virus to the 16th century in a Korean mummy. Hepatology 56(5):1671–1680PubMedCrossRef

World Health Organization (2014) Hepatitis B. Fact sheet N°204, updated July 2014. http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed 6 September 2014

Dane DS, Cameron CH, Briggs M (1970) Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet 1(7649):695–698PubMedCrossRef

Ganem D (1991) Assembly of hepadnaviral virions and subviral particles. Curr Top Microbiol Immunol 168:61–83PubMed

Patient R, Hourioux C, Roingeard P (2009) Morphogenesis of hepatitis B virus and its subviral envelope particles. Cell Microbiol 11(11):1561–1570PubMedCentralPubMedCrossRef

10.

Urban S, Schulze A, Dandri M, Petersen J (2010) The replication cycle of hepatitis B virus. J Hepatol 52(2):282–284PubMedCrossRef

11.

Seeger C, Mason WS (2000) Hepatitis B virus biology. Microbiol Mol Biol Rev 64(1):51–68PubMedCentralPubMedCrossRef

12.

Takahashi K, Machida A, Funatsu G, Nomura M, Usuda S et al (1983) Immunochemical structure of hepatitis B e antigen in the serum. J Immunol 130(6):2903–2907PubMed

13.

Chang C, Enders G, Sprengel R, Peters N, Varmus HE et al (1987) Expression of the precore region of an avian hepatitis B virus is not required for viral replication. J Virol 61(10):3322–3325PubMedCentralPubMed

14.

Chen HS, Kew MC, Hornbuckle WE, Tennant BC, Cote PJ et al (1992) The precore gene of the woodchuck hepatitis virus genome is not essential for viral replication in the natural host. J Virol 66(9):5682–5684PubMedCentralPubMed

15.

Okamoto H, Yotsumoto S, Akahane Y, Yamanaka T, Miyazaki Y et al (1990) Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol 64(3):1298–1303PubMedCentralPubMed

16.

Milich D, Liang TJ (2003) Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology 38(5):1075–1086PubMedCrossRef

17.

Chu C, Yeh C, Lee C, Sheen I, Liaw Y (2002) Precore stop mutant in HBeAg-positive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAg-to-anti-HBe seroconversion. J Clin Microbiol 40(1):16–21PubMedCentralPubMedCrossRef

18.

Zoulim F, Saputelli J, Seeger C (1994) Woodchuck hepatitis virus X protein is required for viral infection in vivo. J Virol 68(3):2026–2030PubMedCentralPubMed

19.

Jazayeri SM, Basuni AA, Sran N, Gish R, Cooksley G et al (2004) HBV core sequence: definition of genotype-specific variability and correlation with geographical origin. J Viral Hepat 11(6):488–501PubMedCrossRef

20.

Norder H, Hammas B, Lee SD, Bile K, Couroucé AM et al (1993) Genetic relatedness of hepatitis B viral strains of diverse geographical origin and natural variations in the primary structure of the surface antigen. J Gen Virol 74(Pt 7):1341–1348PubMedCrossRef

21.

Norder H, Couroucé A, Coursaget P, Echevarria JM, Lee S et al (2004) Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 47(6):289–309PubMedCrossRef

22.

Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW et al (2006) Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 101(2):297–303PubMedCrossRef

23.

Wiegand J, Hasenclever D, Tillmann HL (2008) Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir Ther (Lond) 13(2):211–220

24.

Schulze A, Gripon P, Urban S (2007) Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology 46(6):1759–1768PubMedCrossRef

25.

Yan H, Zhong G, Xu G, He W, Jing Z et al (2012) Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 1:e00049PubMedCentralPubMedCrossRef

26.

Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C et al (2014) Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 146(4):1070–1083PubMedCrossRef

27.

Stieger B, Hagenbuch B, Landmann L, Höchli M, Schroeder A et al (1994) In situ localization of the hepatocytic Na+/Taurocholate cotransporting polypeptide in rat liver. Gastroenterology 107(6):1781–1787PubMed

28.

Hagenbuch B, Meier PJ (1994) Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. J Clin Invest 93(3):1326–1331PubMedCentralPubMedCrossRef

29.

Stieger B (2011) The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation. Handb Exp Pharmacol 201:205–259PubMedCrossRef

30.

Kann M, Schmitz A, Rabe B (2007) Intracellular transport of hepatitis B virus. World J Gastroenterol 13(1):39–47PubMedCentralPubMedCrossRef

31.

Grimm D, Thimme R, Blum HE (2011) HBV life cycle and novel drug targets. Hepatol Int 5(2):644–653PubMedCentralPubMedCrossRef

32.

Pollack JR, Ganem D (1994) Site-specific RNA binding by a hepatitis B virus reverse transcriptase initiates two distinct reactions: RNA packaging and DNA synthesis. J Virol 68(9):5579–5587PubMedCentralPubMed

33.

Tuttleman JS, Pourcel C, Summers J (1986) Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 47(3):451–460PubMedCrossRef

34.

Ganem D, Prince AM (2004) Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med 350(11):1118–1129PubMedCrossRef

35.

Asabe S, Wieland SF, Chattopadhyay PK, Roederer M, Engle RE et al (2009) The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol 83(19):9652–9662PubMedCentralPubMedCrossRef

36.

Ribeiro RM, Lo A, Perelson AS (2002) Dynamics of hepatitis B virus infection. Microbes Infect 4(8):829–835PubMedCrossRef

37.

Kajino K, Jilbert AR, Saputelli J, Aldrich CE, Cullen J et al (1994) Woodchuck hepatitis virus infections: very rapid recovery after a prolonged viremia and infection of virtually every hepatocyte. J Virol 68(9):5792–5803PubMedCentralPubMed

38.

Wieland S, Thimme R, Purcell RH, Chisari FV (2004) Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 101(17):6669–6674PubMedCentralPubMedCrossRef

39.

Dunn C, Peppa D, Khanna P, Nebbia G, Jones M et al (2009) Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 137(4):1289–1300PubMedCrossRef

40.

Chisari FV, Isogawa M, Wieland SF (2010) Pathogenesis of hepatitis B virus infection. Pathol Biol 58(4):258–266PubMedCentralPubMedCrossRef

41.

McMahon BJ (2009) The natural history of chronic hepatitis B virus infection. Hepatology 49(5 Suppl):S45–S55PubMedCrossRef

42.

Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS (2007) Management of hepatitis B: summary of a clinical research workshop. Hepatology 45(4):1056–1075PubMedCrossRef

43.

Yim HJ, Lok AS (2006) Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 43(2 Suppl 1):S173–S181PubMedCrossRef

44.

McMahon BJ (2005) Epidemiology and natural history of hepatitis B. Semin Liver Dis 25(Suppl 1):3–8PubMedCrossRef

45.

Hui C, Leung N, Yuen S, Zhang H, Leung K et al (2007) Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 46(2):395–401PubMedCrossRef

46.

Lok AS, Lai CL, Wu PC, Leung EK, Lam TS (1987) Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 92(6):1839–1843PubMed

47.

Manno M, Cammà C, Schepis F, Bassi F, Gelmini R et al (2004) Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology 127(3):756–763PubMedCrossRef

48.

McMahon BJ, Holck P, Bulkow L, Snowball M (2001) Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 135(9):759–768PubMedCrossRef

49.

Shouval D, Shibolet O (2013) Immunosuppression and HBV reactivation. Semin Liver Dis 33(2):167–177PubMedCrossRef

50.

Raimondo G, Allain J, Brunetto MR, Buendia M, Chen D et al (2008) Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 49(4):652–657PubMedCrossRef

51.

Pollicino T, Raimondo G (2014) Occult hepatitis B infection. J Hepatol 61(3):688–689PubMedCrossRef

52.

Gerlich WH, Bremer C, Saniewski M, Schüttler CG, Wend UC et al (2010) Occult hepatitis B virus infection: detection and significance. Dig Dis 28(1):116–125PubMedCrossRef

53.

Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C et al (2014) Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. World J Hepatol 6(6):384–393PubMedCentralPubMedCrossRef

54.

Beasley RP (1988) Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 61(10):1942–1956PubMedCrossRef

55.

Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J et al (1995) Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP study group on hepatitis B virus and cirrhosis. Hepatology 21(1):77–82PubMed

56.

Moss B, Smith GL, Gerin JL, Purcell RH (1984) Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature 311(5981):67–69PubMedCrossRef

57.

Chen HL, Chang MH, Ni YH, Hsu HY, Lee PI et al (1996) Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 276(11):906–908PubMedCrossRef

58.

Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC et al (1997) Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan childhood hepatoma study group. N Engl J Med 336(26):1855–1859PubMedCrossRef

59.

Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA et al (2003) CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 77(1):68–76PubMedCentralPubMedCrossRef

60.

Webster GJ, Reignat S, Maini MK, Whalley SA, Ogg GS et al (2000) Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 32(5):1117–1124PubMedCrossRef

61.

Ferrari C, Penna A, Bertoletti A, Valli A, Antoni AD et al (1990) Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 145(10):3442–3449PubMed

62.

Rehermann B, Fowler P, Sidney J, Person J, Redeker A et al (1995) The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 181(3):1047–1058PubMedCrossRef

63.

Jung MC, Hartmann B, Gerlach JT, Diepolder H, Gruber R et al (1999) Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection. Virology 261(2):165–172PubMedCrossRef

64.

Webster GJM, Reignat S, Brown D, Ogg GS, Jones L et al (2004) Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B Virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 78(11):5707–5719PubMedCentralPubMedCrossRef

65.

Wherry EJ (2011) T cell exhaustion. Nat Immunol 131(6):492–499CrossRef

66.

Sauce D, Almeida JR, Larsen M, Haro L, Autran B et al (2007) PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status. AIDS 21(15):2005–2013PubMedCrossRef

67.

Bengsch B, Martin B, Thimme R (2014) Restoration of HBV-specific CD8+ T-cell function by PD-1 blockade in inactive carrier patients is linked to T-cell differentiation. J Hepatol 61(6):1212–1219PubMedCrossRef

68.

Blackburn SD, Wherry EJ (2007) IL-10, T cell exhaustion and viral persistence. Trends Microbiol 15(4):143–146PubMedCrossRef

69.

Akcam FZ, Tigli A, Kaya O, Ciris M, Vural H (2012) Cytokine levels and histopathology in chronic hepatitis B and chronic hepatitis C. J Interferon Cytokine Res 32(12):570–574PubMedCrossRef

70.

Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB et al (2006) Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 12(11):1301–1309PubMedCentralPubMedCrossRef

71.

Ejrnaes M, Filippi CM, Martinic MM, Ling EM, Togher LM et al (2006) Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med 203(11):2461–2472PubMedCentralPubMedCrossRef

72.

Das A, Hoare M, Davies N, Lopes AR, Dunn C et al (2008) Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med 205(9):2111–2124PubMedCentralPubMedCrossRef

73.

Bertoletti A, Ferrari C (2012) Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 61(12):1754–1764PubMedCrossRef

74.

Yang PL, Althage A, Chung J, Maier H, Wieland S et al (2010) Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci USA 107(2):798–802PubMedCentralPubMedCrossRef

75.

Peppa D, Gill US, Reynolds G, Easom NJW, Pallett LJ et al (2013) Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. J Exp Med 210(1):99–114PubMedCentralPubMedCrossRef

76.

Andrews DM, Scalzo AA, Yokoyama WM, Smyth MJ, Degli-Esposti MA (2003) Functional interactions between dendritic cells and NK cells during viral infection. Nat Immunol 4(2):175–181PubMedCrossRef

77.

Krueger PD, Lassen MG, Qiao H, Hahn YS (2011) Regulation of NK cell repertoire and function in the liver. Crit Rev Immunol 31(1):43–52PubMedCentralPubMedCrossRef

78.

Lassen MG, Lukens JR, Dolina JS, Brown MG, Hahn YS (2010) Intrahepatic IL-10 maintains NKG2A+Ly49-liver NK cells in a functionally hyporesponsive state. J Immunol 184(5):2693–2701PubMedCentralPubMedCrossRef

79.

Tu Z, Bozorgzadeh A, Pierce RH, Kurtis J, Crispe IN et al (2008) TLR-dependent cross talk between human Kupffer cells and NK cells. J Exp Med 205(1):233–244PubMedCentralPubMedCrossRef

80.

Oliviero B, Varchetta S, Paudice E, Michelone G, Zaramella M et al (2009) Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 137(3):1151–1160 1160.e1–7PubMedCrossRef

81.

Peppa D, Micco L, Javaid A, Kennedy PT, Schurich A et al (2010) Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog 6(12):e1001227PubMedCentralPubMedCrossRef

82.

Shi CC, Tjwa ETTL, Biesta PJ, Boonstra A, Xie Q et al (2012) Hepatitis B virus suppresses the functional interaction between natural killer cells and plasmacytoid dendritic cells. J Viral Hepat 19(2):e26–e33PubMedCrossRef

83.

Maini MK, Peppa D (2013) NK cells: a double-edged sword in chronic hepatitis B virus infection. Front Immunol 4:57PubMedCentralPubMedCrossRef

84.

Radaeva S, Sun R, Jaruga B, van Nguyen T, Tian Z et al (2006) Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 130(2):435–452PubMedCrossRef

85.

Lang PA, Lang KS, Xu HC, Grusdat M, Parish IA et al (2012) Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity. Proc Natl Acad Sci USA 109(4):1210–1215PubMedCentralPubMedCrossRef

86.

Waggoner SN, Cornberg M, Selin LK, Welsh RM (2012) Natural killer cells act as rheostats modulating antiviral T cells. Nature 481(7381):394–398

Titel: Natural history of chronic hepatitis B virus infection
verfasst von: Katrin Busch
Robert Thimme
Publikationsdatum: 01.02.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Medical Microbiology and Immunology / Ausgabe 1/2015
Print ISSN: 0300-8584
Elektronische ISSN: 1432-1831
DOI: https://doi.org/10.1007/s00430-014-0369-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Natural history of chronic hepatitis B virus infection

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2015

Antiviral therapy for chronic hepatitis B in China

Therapeutic vaccines in HBV: lessons from HCV

Electroporation for therapeutic DNA vaccination in patients

Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck

Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection

Circumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response?

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin